Results 81 to 90 of about 1,440 (183)

First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

Journal of Hematology & Oncology, 2018
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematological malignancy with extremely poor outcome. The median overall survival for adult patients is 9–13 months.
Weili Sun, Huaying Liu, Young Kim, Nicole Karras, Anna Pawlowska, Debbie Toomey, Wade Kyono, Paul Gaynon, Joseph Rosenthal, Anthony Stein   +9 more
doaj   +1 more source

Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm

Journal of Investigative Medicine High Impact Case Reports, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed
Prashanth Ashok Kumar MBBS, Mulham Ombada MBBS, Gayatri Pemmasani MBBS, Ajay Tambe MBBS, Katalin Banki MD, Teresa Gentile MD, PhD   +5 more
doaj   +1 more source

Two Blastic Plasmacytoid Dendritic Cell Neoplasms treated with the CD123‐targeted agent Tagraxofusp presenting divergent outcomes

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven C. Engler, Elisabeth M. Walde, Edgar Jost, Amir S. Yazdi, David Kluwig   +4 more
wiley   +1 more source

Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Myeloid sarcoma (MS) is a tumorous extramedullary proliferation of blast or blast equivalent cells (e.g., promonocytes or promyelocytes). The most frequent cutaneous presentation is often referred to as leukemia cutis (LC). These lesions, especially without the clinical context of a known bone marrow disease, pose a differential diagnostic ...
Alex Jenei, Béla Kajtár, Tamás László, Hazem A Juratli, Livia Vida, Ágota Szepesi, Réka Mózes, Botond Timár, Jörg Halter, Stefan Dirnhofer, Alexandar Tzankov   +10 more
wiley   +1 more source

PRMT5 Inhibition Affects RNA Methylation and Is a Potential Therapeutic Target in BPDCN

Blood, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic cancer that arises from malignant transformation of plasmacytoid dendritic cells (pDCs) and is predisposed to leukemic transformation. Apart from the recently approved therapy, Tagraxofusp-erzs, treatment options for BPDCN remain limited.
Malini Rethnam, Darren Qiancheng Tan, Shi Hao Tan, Li Ying, Henry Yang, Toshio Suda   +5 more
openaire   +1 more source

Structural design and property regulation of organic polymers for photocatalytic synthesis of H2O2

InfoScience, Volume 3, Issue 1, March 2026.
Photocatalytic synthesis of H2O2 offers a sustainable approach. Photocatalytic efficiency depends critically on interfacial electron transfer kinetics and spatial charge separation. Herein, we systematically analyze key factors governing photogenerated carrier dynamics and propose engineered strategies to optimize performance, thereby providing design ...
Mingyang Xu, Rongchen Shen, Yingyin Mo, Guijie Liang, Shijie Li, Peng Zhang, Xiaobo Chen, Youji Li, Xin Li   +8 more
wiley   +1 more source

Safety and Efficacy of Adoptive Transfer of Stem Cell Memory Enriched Virus Specific T Cells against CMV and EBV

Advanced Science, Volume 13, Issue 9, 13 February 2026.
This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao, Xu‐Ying Pei, Yuan‐Yuan Zhang, Juan Xie, Jing‐Wei Tu, Zhuo‐Jun Liu, Yi‐Yang Ding, Chen‐Hua Yan, Yu‐Hong Chen, Yu Wang, Lan‐Ping Xu, Xiao‐Hui Zhang, Xiao‐Jun Huang, Xiang‐Yu Zhao   +13 more
wiley   +1 more source

CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm

, 2022
SIMPLE SUMMARY: Until recently, there were no approved therapies for the aggressive blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN). Survival for patients diagnosed with BPDCN is under two years, and improved treatments are needed.
Naveen Pemmaraju, Caël, Blandine, Daguindau, Etienne, Lane, Andrew A., Blandine Caël, Etienne Daguindau, Pemmaraju, Naveen, Elodie Bôle-Richard, Bôle-Richard, Elodie, Andrew A. Lane   +9 more
core   +1 more source

眼巩膜受侵母细胞性浆细胞样树突状细胞肿瘤1例并文献复习

Zhongguo shiyan zhenduanxue, 2017
母细胞性浆细胞样树突状细胞肿瘤（blastic plasmacytoid dendritic cell neoplasm,BPDCN）是一种罕见的血液系统恶性肿瘤,易侵犯皮肤和骨髓,目前的诊断还没有完全特征性的指标,治疗上亦无标准有效的治疗手段。BPDCN的发病以老年人居多,现总结我科收治的1例青年男性BPDCN患者临床资料,并结合国内外报道的BPDCN病例,回顾性分析患者的临床特征,提高临床医生对BPDCN的诊疗水平。1病例资料患者,男性,25岁 ...
刘芳, 朱耿军, 任立参, 沈卫章, 赵岩, 徐文   +5 more
doaj  

A systematic literature review of 74 Chinese blastic plasmacytoid dendritic cell neoplasm patients

Therapeutic Advances in Hematology
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological cancer. Due to its low incidence, researchers struggle to gather sufficient prospective data to inform clinical treatment.
Chen Gong, Ying Liu, Mingzhi Zhang
doaj   +1 more source